



To: Carter BloodCare Customers
From: Hospital Relations Department
Date: November 30, 2018
Re: Zika licensed assay and Circular of Information

Effective immediately, testing for Zika virus will be performed with the recently licensed assay; therefore, a modification to the Circular of Information regarding Zika Virus testing must be updated to reflect this practice.

In accordance with Food and Drug Administration (FDA) Guidance for Industry: An Acceptable Circular of Information for the Use of Human Blood and Blood Components, October 2017, can be found at the link below:

<http://www.aabb.org/tm/coi/Documents/coi1017.pdf>

Please note: The following information is to be considered a part of the Circular of Information as it applies to the General Information for Whole Blood and All Blood Components, Testing of Donor Blood section.

A licensed nucleic acid test (NAT) for Zika Virus RNA has been performed and found to be nonreactive.

Additionally, printed copies of the Circular of Information requested from Carter BloodCare will contain this statement.